Are you Dr. Hurwitz?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 97 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2100 Erwin Rd
Durham, NC 27710Phone+1 919-620-4467- Is this information wrong?
Summary
- Dr. Herbert Hurwitz, MD is an oncologist in Durham, North Carolina. He is currently licensed to practice medicine in North Carolina. He is an Associate Professor at Duke University School of Medicine.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1992 - 1995
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1988 - 1991
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1988
Certifications & Licensure
NC State Medical License 1996 - 2024
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2007 Mar 01
- BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) Start of enrollment: 2007 Nov 01
- Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus Start of enrollment: 2007 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD dat...Ofer Margalit, William S Harmsen, Einat Shacham-Shmueli, Molly M Voss, Ben Boursi, Anna D Wagner, Romain Cohen, Curtis L Olswold, Leonard B Saltz, Daniel A Goldstein, ...> ;European Journal of Cancer. 2023 Nov 1
- Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCA...Fang-Shu Ou, Daniel H Ahn, Jesse G Dixon, Axel Grothey, Yiyue Lou, Pashtoon M Kasi, Joleen M Hubbard, Eric Van Cutsem, Leonard B Saltz, Hans-Joachim Schmoll, Richard M...> ;Cancers. 2023 Aug 15
- 9 citationsPhase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.Christian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, Byoung Chul Cho, David Hong, Keunchil Park, Karen L Reckamp, Sunil Sharma, Hirak Der-Torossian, James G...> ;Targeted Oncology. 2023 Jan 1
- Join now to see all
Grant Support
- Wound Angiogenesis As A Biomarker For Tumor AngiogenesisNational Cancer Institute2006–2010
- Anti-Vegf In Tumors &Wounds: Efficacy VS ToxicityNational Cancer Institute2006–2010
- Biomarker And Clinical Evaluation Of Bevacizumab (AVASTIN) To Determine The RoleNational Center For Research Resources2005
- New Clinical Biomarker For Cancer--Wound AngiogenesisNational Cancer Institute2000–2005
- Nitric Oxide In Anti-Vegf TherapyNational Center For Research Resources2004
- Does NO Mediate Clinical Anti-Vegf Vascular EffectsNational Cancer Institute2003–2004
- PH I: Two Week PO Administration SCH 66336 Advanced CancerNational Center For Research Resources1999–2002
- PH 1 Xrt+5 Fu+Eniluracil--Advanced Unresectable Upper GI MalignanciesNational Center For Research Resources1999–2002
- Bioequivalence Combination 776c85/5fu Pill &Individual 776c85 &5fu PillNational Center For Research Resources1998–2002
- Surrogate Markers Of Angiogenesis In Patients Treated With Anti-Angiogenic AgentsNational Center For Research Resources2000
- Phase I Trial To Evaluate The Safety &Tolerability Of Topoisomerase I InhibitorNational Center For Research Resources2000
- Evaluate Potential Surrogate Markers Of Angiogenesis In Normal VolunteersNational Center For Research Resources2000
Professional Memberships
- Member
